Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and HXTC for persistent HIV infection
NCT03212989Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jun 2017
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HXTC in human immunodeficiency virus infection (HIV), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Number of Participants w/ at Least One >= Grade 3 Adverse Event That is Possibly or Definitely Related to Vorinostat (VOR) or HIV-specific T Cell (HXTC). Started Jun 2017; status: completed.
02
Drugs
HXTC
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03212989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212989.